Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

Jingran Ji,Jacqueline V. Aredo,Andrew J. Piper-Vallillo,Laura A. Huppert,Julia Rotow,Hatim Husain,Susan L. Stewart,Rosemary Cobb,Heather A. Wakelee,Collin M. Blakely,Melisa L. Wong,Matthew A. Gubens,Justin Chen,Geoffrey R. Oxnard,Caroline E. McCoach,Zofia Piotrowska,Joel W. Neal,Jonathan W. Riess

Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.

2020

Jingran Ji
Jacqueline V. Aredo
Andrew J. Piper-Vallillo
Laura A. Huppert
Julia Rotow
Hatim Husain
Susan L. Stewart
Rosemary Cobb
Heather A. Wakelee
Collin M. Blakely
Melisa L. Wong
Matthew A. Gubens
Justin Chen
Geoffrey R. Oxnard
Caroline E. McCoach
Zofia Piotrowska
Joel W. Neal
Jonathan W. Riess

9570Background: Osimertinib (osi) is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) approved for first line (1L) treatment of metastatic NSCLC harboring EGFR Exon 19 del and L858R (represent...

Keywords:

Osimertinib
Oncology
multicenter study
Internal medicine
Pathology
Medicine
non-small cell lung cancer (NSCLC)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations